Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Published:2019-07 Issue:7 Volume:7 Page:569-580
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Scagliotti Giorgio V,Gaafar Rabab,Nowak Anna K,Nakano Takashi,van Meerbeeck Jan,Popat Sanjay,Vogelzang Nicholas J,Grosso Federica,Aboelhassan Rasha,Jakopovic Marko,Ceresoli Giovanni L,Taylor Paul,Orlandi Francisco,Fennell Dean A,Novello Silvia,Scherpereel Arnaud,Kuribayashi Kozo,Cedres Susana,Sørensen Jens Benn,Pavlakis Nick,Reck Martin,Velema Derek,von Wangenheim Ute,Kim Miyoung,Barrueco José,Tsao Anne S

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline;Kindler;J Clin Oncol,2018

2. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Baas;Ann Oncol,2015

3. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

4. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

5. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops;Masood;Int J Cancer,2003

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. New Treatment for Pleural Mesothelioma;Haigan;2024-08-20

3. Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects;Current Cancer Therapy Reviews;2024-07-23

4. Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial;The Lancet Oncology;2024-07

5. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03